ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.
根据最新的财务报表(Form-10K),ProUroCare Medical Inc 的总资产为 $0,净损失为 $-2
PUMD 的关键财务比率是什么?
ProUroCare Medical Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
ProUroCare Medical Inc 的收入按细分市场或地理位置如何划分?
ProUroCare Medical Inc 最大收入来源是 Custom Smelting & Products,在最近的收益报告中收入为 16,660,588,000。就地区而言, Other European Union Countries 是 ProUroCare Medical Inc 的主要市场,收入为 5,790,892,000。